Literature DB >> 1405318

Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model.

F Terzi1, H Beaufils, D Laouari, M Burtin, C Kleinknecht.   

Abstract

Angiotensin converting enzyme inhibitors (ACEI) are believed to protect remnant kidney, but all previous studies used the ligation model which causes severe hypertension, and very few have compared drugs in rats having similar control of blood pressure (BP). We compared rats with uremia obtained by 70% excision of total renal mass, a model which causes mild, late hypertension. Study I compared the effects of enalapril (E), cicletanine (C) and placebo (P) in uremic (U) rats fed a 0.50% (normal-high) Na diet. Study II compared the effects of E, C, P, and guanfacine (G) in U rats fed a diet restricted to 0.25% Na (normal-low). In study I, UP rats developed progressive hypertension (140, 146, 160 and 166 mm Hg at 3, 6, 9 and 12 weeks), proteinuria (240 mg/day at 9 and 12 weeks) which were not affected by E or C. The occurrence of end-stage renal disease (ESRD) led to the sacrifice of all rats after three months. All three groups had similar severe renal lesions (over 25% sclerosed glomeruli in 5 of 10 UP, 9 of 14 UE, 7 of 14 UC rats, with huge cystic tubular dilatations). In study II, rats could be sacrificed later (6 months) and had evidence of less severe renal disease. All the drugs tested prevented hypertension throughout the study (P less than 0.001), with lowest values in UE rats. E and G, but not C, reduced proteinuria. Renal damage was reduced with E and G, but not with C, despite similar BP in C and G rats. Thus, in contrast with what was obtained in the ligation model, ACEI affected neither the BP nor the renal lesions of rats made uremic by renal excision and fed a 0.50% Na diet. Moderate Na restriction improved the consequences of nephron loss and restored the anti-hypertensive effect of drugs. However, these drugs had a different effect on renal preservation: it was dramatic with E, good with G, and undetectable with C.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405318     DOI: 10.1038/ki.1992.296

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance.

Authors:  F Terzi; D Henrion; E Colucci-Guyon; P Federici; C Babinet; B I Levy; P Briand; G Friedlander
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

2.  Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury.

Authors:  F Terzi; M Burtin; M Hekmati; P Federici; G Grimber; P Briand; G Friedlander
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  Long-term therapy with enalapril in patients with nephrotic-range proteinuria.

Authors:  W Proesmans; I V Wambeke; M V Dyck
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions.

Authors:  E Pillebout; M Burtin; H T Yuan; P Briand; A S Woolf; G Friedlander; F Terzi
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate.

Authors:  B L Wharram; M Goyal; P J Gillespie; J E Wiggins; D B Kershaw; L B Holzman; R C Dysko; T L Saunders; L C Samuelson; R C Wiggins
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  JunD protects against chronic kidney disease by regulating paracrine mitogens.

Authors:  Evangéline Pillebout; Jonathan B Weitzman; Martine Burtin; Carla Martino; Pierre Federici; Moshe Yaniv; Gérard Friedlander; Fabiola Terzi
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

7.  Signaling pathways predisposing to chronic kidney disease progression.

Authors:  Mohamad Zaidan; Martine Burtin; Jitao David Zhang; Thomas Blanc; Pauline Barre; Serge Garbay; Clément Nguyen; Florence Vasseur; Lucie Yammine; Serena Germano; Laura Badi; Marie-Claire Gubler; Morgan Gallazzini; Gérard Friedlander; Marco Pontoglio; Fabiola Terzi
Journal:  JCI Insight       Date:  2020-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.